HeraMED announces Gold Coast trial of HeraCARE platform

Latest News

Medical data and technology company HeraMED (ASX:HMD) has announced that it has signed a memorandum of understanding with the Gold Coast Hospital to trial its HeraCARE platform as a new standard of care for their Women Newborn and Children Services (WNCS).

The company said that initially, a controlled trial of the HeraCARE platform will be undertaken for up to 90 pregnancies for a period of six to nine months with an objective to evaluate clinical usability, patient satisfaction, value for money and economic analysis.

HeraMED will work with Gold Coast Health to undertake a clinical implementation study to assess several use cases including acceptance, cost-effective analysis and clinical outcomes.

HeraMED CEO and co-founder David Groberman said, “This MOU represents a significant milestone for HeraMED and an important validation of our technology and business model and is our first major win with a government establishment on the Australian East Coast.

“I would like to take this opportunity to congratulate the entire team and in particular Anoushka Gungadin and Ady Jakubovitz, who have successfully navigated the rigorous evaluation and testing processes that exist across healthcare, to finalise this MOU.

“The Gold Coast Hospital is leading the way in the digitisation of healthcare, and we are delighted that they are planning to adopt our technology as their standard of care for remote pregnancy monitoring,” he said.

Gold Coast Health executive director of strategy, transformation and major capital, Sandip Kumar, added, “Having successfully completed the first stage of our transformation agenda which was to digitally enable our health service, the focus now is to leverage new technologies to improve the quality and experience of patient care and we expect the HeraCARE platform will deliver on these goals as our new standard of care.